C5 Antigens and Uses Thereof
AssigneeNovartis AG
InventorsBraydon Charles Guild, Mark Taylor Keating, Mariusz Milik, Dmitri Mikhailov, Michael Roguska, Igor Splawski, Kehao Zhao
Life of this patent
Estimating the term…
Abstract
The present invention pertains to the use of a complement inhibitor in methods of treatment of ocular disorders and the use of a complement inhibitor in the manufacture of a medicament in the treatment of an ocular disorder.
Claims39
An isolated polynucleotide having at least 95% nucleic acid sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID Nos. 2, 4, and 6.
An isolated polynucleotide comprising a nucleic acid sequence selected from the group consisting of SEQ ID Nos. 2, 4, and 6.
An isolated polypeptide having at least 95% amino acid identity to an amino acid sequence selected from the group consisting SEQ ID Nos 1, 3 and 5.
An isolated polypeptide comprising an amino acid sequence selected from the group consisting SEQ ID Nos 1, 3 and 5.
An isolated C5 binding molecule comprising an antigen binding portion of an antibody that specifically binds to a C5 epitope within or overlapping amino acids selected from the group consisting of SEQ ID Nos 1, 3 and 5.
The C5 binding molecule of any preceding claim, wherein the antigen binding portion is an antigen binding portion of a human antibody.
A method of inhibiting MAC synthesis in a cell, the method comprising contacting a cell with a C5 binding molecule.
A method of modulating MAC activity in a subject, the method comprising administering to the subject a C5 binding molecule that modulates cellular activities mediated by the complement system.
A method of treating or preventing an ocular disorder in a subject, the method comprising administering to the subject an effective amount of a binding molecule which specifically binds to an epitope selected from SEQ ID Nos. 1, 3 and 5.
-40. (canceled)
A method of treating or inhibiting an ocular disease or disorder, or delaying their progression;
- the method comprising administering an effective amount of a protein capable of inhibiting the alternate complement pathway to a subject in need of such treatment.
Dependencies are inferred from the claim text.